Share This Article:

Phenotypic Characteristics and Function of NK Cell Subsets in cART-Treated HIV-1-Infected Individuals

Abstract Full-Text HTML Download Download as PDF (Size:2731KB) PP. 293-300
DOI: 10.4236/wja.2014.43034    2,393 Downloads   2,842 Views   Citations

ABSTRACT

Natural killer (NK) cell plays an important role in an innate immune response against viral infection. The kinetics regulation and functional consequences of NK cells in the pathogeneses of diseases are uncertain. We analyzed NK cell distribution and function of successfully combination antiretroviral therapy (cART)-treated HIV-1 infected individuals in Khon Kaen Regional Hospital, Thailand. The results demonstrated that increased percentage and the total number of NK cell in cART-treated HIV-1 infected patients with preferential high levels of CD56dimCD16+ and CD56-CD16+ subsets when compared with a control group even in undetectable viral load (<40 copies per milliliter). Concomitantly, decreased cytotoxic activity measured by CD107asurface expression with maintained IFN-γ production implied the impairment of cytolytic activity was not recovered after cART treatment. Thus, altered NK cell frequency and function by HIV-1 infection are not completely recovered with cART, which may contribute to impaired cellular immune response and persistence of HIV-1.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Mitchai, M. , Leeratanapetch, N. , Lulitanond, V. , Srikoon, P. , Hattori, S. , Vaeteewoottacharn, K. , Wongkham, S. and Okada, S. (2014) Phenotypic Characteristics and Function of NK Cell Subsets in cART-Treated HIV-1-Infected Individuals. World Journal of AIDS, 4, 293-300. doi: 10.4236/wja.2014.43034.

References

[1] Lodoen, M.B. and Lanier, L.L. (2006) Natural Killer Cells as an Initial Defense against Pathogens. Current Opinion in Immunology, 18, 391-398. http://dx.doi.org/10.1016/j.coi.2006.05.002
[2] Cooper, M.A., Fehniger, T.A. and Caligiuri, M.A. (2001) The Biology of Human Natural Killer-Cell Subsets. Trends in Immunology, 22, 633-640. http://dx.doi.org/10.1016/S1471-4906(01)02060-9
[3] Caligiuri, M.A. (2008) Human Natural Killer Cells. Blood, 112, 461-469.
http://dx.doi.org/10.1182/blood-2007-09-077438
[4] Penack, O., Gentilini, C., Fischer, L., Asemissen, A.M., Scheibenbogen, C., Thiel, E. and Uharek, L. (2005) CD56dimCD16neg Cells Are Responsible for Natural Cytotoxicity against Tumor Targets. Leukemia, 19, 835-840. http://dx.doi.org/10.1038/sj.leu.2403704
[5] Alter, G. and Altfeld, M. (2009) NK Cells in HIV-1 Infection: Evidence for Their Role in the Control of HIV-1 Infection. Journal of Internal Medicine, 265, 29-42.
http://dx.doi.org/10.1111/j.1365-2796.2008.02045.x
[6] Naranbhai, V., Altfeld, M., Karim, S.S., Ndung’u, T., Karim, Q.A. and Carr, W.H. (2013) Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection. PLoS ONE, 8, Article ID: e53251. http://dx.doi.org/10.1371/journal.pone.0053251
[7] Alter, G., Teigen, N., Davis, B.T., Addo, M.M., Suscovich, T.J., Waring, M.T., Streeck, H., Johnston, M.N., Staller, K.D., Zaman, M.T., Yu, X.G., Lichterfeld, M., Basgoz, N., Rosenberg, E.S. and Altfeld, M. (2005) Sequential Deregulation of NK Cell Subset Distribution and Function Starting in Acute HIV-1 Infection. Blood, 106, 3366-3369. http://dx.doi.org/10.1182/blood-2005-03-1100
[8] Mavilio, D., Lombardo, G., Benjamin, J., Kim, D., Follman, D., Marcenaro, E., O’Shea, M.A., Kinter, A., Kovacs, C., Moretta, A. and Fauci, A.S. (2005) Characterization of CD56-/CD16+ Natural Killer (NK) Cells: A Highly Dysfunctional NK Subset Expanded in HIV-Infected Viremic Individuals. Proceedings of National Academy of Science of the Unite States of America, 102, 2886-2891.
http://dx.doi.org/10.1073/pnas.0409872102
[9] Mavilio, D., Lombardo, G., Kinter, A., Fogli, M., La Sala, A., Ortolano, S., Farschi, A., Follmann, D., Gregg, R., Kovacs, C., Marcenaro, E., Pende, D., Moretta, A. and Fauci, A.S. (2006) Characterization of the Defective Interaction between a Subset of Natural Killer Cells and Dendritic Cells in HIV-1 Infection. Journal of Experimental Medicine, 203, 2339-2350.
http://dx.doi.org/10.1084/jem.20060894
[10] Alter, G., Malenfant, J.M., Delabre, R.M., Burgett, N.C., Yu, X.G., Lichterfeld, M., Zaunders, J. and Altfeld, M. (2004) Increased Natural Killer Cell Activity in Viremic HIV-1 Infection. The Journal of Immunology, 173, 5305-5311. http://dx.doi.org/10.4049/jimmunol.173.8.5305
[11] UNAIDS/World Health Organization (2014) Report on the Global HIV/AIDS Epidemic, 2013. UNAIDS, Geneva. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/ gr2013/unaids_global_report_2013_en.pdf
[12] Kallings, L.O. (2008) The First Postmodern Pandemic: 25 Years of HIV/AIDS. Journal of Internal Medicine, 263, 218-243. http://dx.doi.org/10.1111/j.1365-2796.2007.01910.x
[13] Bhaskaran, K., Hamouda, O., Sannes, M., Boufassa, F., Johnson, A.M., Lambert, P.C. and Porter, K. (2008) Changes in the Risk of Death after HIV Seroconversion Compared with Mortality in the General Population. JAMA, 300, 51-59. http://dx.doi.org/10.1001/jama.300.1.51
[14] Lau, B., Gange, S.J. and Moore, R.D. (2007) Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality among Individuals Enrolling into Care with CD4+ Counts Greater than 200 Cells/mm3. The Journal of Acquired Immune Deficiency Syndromes, 44, 179-187.
http://dx.doi.org/10.1097/01.qai.0000247229.68246.c5
[15] Gaardbo, J.C., Hartling, H.J., Gerstoft, J. and Nielsen, S.D. (2012) Incomplete Immune Recovery in HIV Infection: Mechanisms, Relevance for Clinical Care, and Possible Solutions. Clinical and Developmental Immunology, 2012, Article ID: 670957. http://dx.doi.org/10.1155/2012/670957
[16] Dessouki, O., Kamiya, Y., Nagahama, H., Tanaka, M., Suzu, S., Sasaki, Y. and Okada, S. (2010) Chronic Hepatitis C Viral Infection Reduces NK Cell Frequency and Suppresses Cytokine Secretion: Reversion by Anti-Viral Treatment. Biochemical and Biophysical Research Communications, 393, 331-337. http://dx.doi.org/10.1016/j.bbrc.2010.02.008
[17] Alter, G., Malenfant, J.M. and Altfeld, M. (2004) CD107a as a Functional Marker for the Identification of Natural Killer Cell Activity. Journal of Immunological Methods, 294, 15-22.
http://dx.doi.org/10.1016/j.jim.2004.08.008
[18] Bonnet, F., Burty, C., Lewden, C., Costagliola, D., May, T., Bouteloup, V., Rosenthal, E., Jougla, E., Cacoub, P., Salmon, D., Chene, G. and Morlat, P. (2009) Changes in Cancer Mortality among HIV-Infected Patients: The Mortalite 2005 Survey. Clinical Infectious Disease, 48, 633-639.
http://dx.doi.org/10.1086/596766
[19] Gonzalez, V.D., Falconer, K., Michaelsson, J., Moll, M., Reichard, O., Alaeus, A. and Sandberg, J.K. (2008) Expansion of CD56-NK Cells in Chronic HCV/HIV-1 Co-Infection: Reversion by Antiviral Treatment with Pegylated IF-Nalpha and Ribavirin. Clinical Immunology, 128, 46-56.
http://dx.doi.org/10.1016/j.clim.2008.03.521
[20] Bjorkstrom, N.K., Ljunggren, H.G. and Sandberg, J.K. (2010) CD56 Negative NK Cells: Origin, Function, and Role in Chronic Viral Disease. Trends in Immunology, 31, 401-406.
http://dx.doi.org/10.1016/j.it.2010.08.003
[21] Fauci, A.S., Mavilio, D. and Kottilil, S. (2005) NK Cells in HIV Infection: Paradigm for Protection or Targets for Ambush. Nature Reviews-Immunology, 5, 835-843. http://dx.doi.org/10.1038/nri1711
[22] Hong, H.S., Eberhard, J.M., Keudel, P., Bollmann, B.A., Ahmad, F., Ballmaier, M., Bhatnagar, N., Zielinska-Skowronek, M., Schmidt, R.E. and Meyer-Olson, D. (2010) Phenotypically and Functionally Distinct Subsets Contribute to the Expansion of CD56?/CD16+ Natural Killer Cells in HIV Infection. AIDS, 24, 1823-1834. http://dx.doi.org/10.1097/QAD.0b013e32833b556f
[23] Fan, Y.Y., Yang, B.Y. and Wu, C.Y. (2008) Phenotypically and Functionally Distinct Subsets of Natural Killer Cells in Human PBMCs. Cell Biology International, 32, 188-197.
http://dx.doi.org/10.1016/j.cellbi.2007.08.025
[24] Mantegani, P., Tambussi, G., Galli, L., Din, C.T., Lazzarin, A. and Fortis, C. (2010) Perturbation of the Natural Killer Cell Compartment during Primary Human Immunodeficiency Virus 1 Infection Primarily Involving the CD56 Bright Subset. Immunology, 129, 220-233. http://dx.doi.org/10.1111/j.1365-2567.2009.03171.x
[25] Strbo, N., de Armas, L., Liu, H., Kolber, M.A., Lichtenheld, M. and Pahwa, S. (2008) IL-21 Augments Natural Killer Effector Functions in Chronically HIV-Infected Individuals. AIDS, 22, 1551-1560.
http://dx.doi.org/10.1097/QAD.0b013e3283089367
[26] Streeck, H., Jessen, H., Alter, G., Teigen, N., Waring, M.T., Jessen, A., Stahmer, I., van Lunzen, J., Lichterfeld, M., Gao, X., Allen, T.M., Carrington, M., Walker, B.D., Rockstroh, J.K. and Altfeld, M. (2006) Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during Acute HIV-1 Infection. Journal of Infectious Diseases, 194, 734-739. http://dx.doi.org/10.1086/503811
[27] Alter, G., Teigen, N., Ahern, R., Streeck, H., Meier, A., Rosenberg, E.S. and Altfeld, M. (2007) Evolution of Innate and Adaptive Effector Cell Functions during Acute HIV-1 Infection. Journal of Infectious Diseases, 195, 1452-1460. http://dx.doi.org/10.1086/513878
[28] Michaelsson, J., Long, B.R., Loo, C.P., Lanier, L.L., Spotts, G., Hecht, F.M. and Nixon, D.F. (2008) Immune Reconstitution of CD56dim NK Cells in Individuals with Primary HIV-1 Infection Treated with Interleukin-2. Journal of Infectious Diseases, 197, 117-125. http://dx.doi.org/10.1086/524141

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.